- Home
- RSVR vs DNA Comparison
RSVR vs DNA Comparison
Compare RSVR & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- DNA
- Stock Information
- Founded
- RSVR 2007
- DNA 2008
- Country
- RSVR United States
- DNA United States
- Employees
- RSVR N/A
- DNA N/A
- Industry
- RSVR Movies/Entertainment
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSVR Consumer Discretionary
- DNA Health Care
- Exchange
- RSVR Nasdaq
- DNA Nasdaq
- Market Cap
- RSVR 528.3M
- DNA 478.8M
- IPO Year
- RSVR N/A
- DNA N/A
- Fundamental
- Price
- RSVR $7.13
- DNA $7.85
- Analyst Decision
- RSVR Strong Buy
- DNA Sell
- Analyst Count
- RSVR 1
- DNA 5
- Target Price
- RSVR $12.50
- DNA $17.25
- AVG Volume (30 Days)
- RSVR 40.4K
- DNA 1.6M
- Earning Date
- RSVR 05-29-2025
- DNA 05-08-2025
- Dividend Yield
- RSVR N/A
- DNA N/A
- EPS Growth
- RSVR 4113.60
- DNA N/A
- EPS
- RSVR 0.12
- DNA N/A
- Revenue
- RSVR $156,433,584.00
- DNA $227,043,000.00
- Revenue This Year
- RSVR $10.97
- DNA N/A
- Revenue Next Year
- RSVR $6.81
- DNA $16.85
- P/E Ratio
- RSVR $59.94
- DNA N/A
- Revenue Growth
- RSVR 11.32
- DNA N/A
- 52 Week Low
- RSVR $6.56
- DNA $5.00
- 52 Week High
- RSVR $9.83
- DNA $45.20
- Technical
- Relative Strength Index (RSI)
- RSVR 44.06
- DNA 53.59
- Support Level
- RSVR $6.89
- DNA $7.93
- Resistance Level
- RSVR $7.29
- DNA $8.58
- Average True Range (ATR)
- RSVR 0.45
- DNA 0.81
- MACD
- RSVR 0.00
- DNA 0.36
- Stochastic Oscillator
- RSVR 47.50
- DNA 77.24
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.